Degarelix

L02BX02

Template: Infobox chemical / molecular formula search available

Degarelix is a synthetic peptide, which is used as a drug for the treatment of hormone-dependent prostate cancer. It is a so-called GnRH blocker, which causes a rapid reduction in testosterone levels within a few days and achieved a similar immediate effect after orchidectomy. Conventional hormone preparations, so-called GnRH agonists cause only after several weeks, a reduction in testosterone levels.

Once the drug is approved in the U.S. in December 2008, issued on 17 February 2009, the European Commission the company Ferring Holding SA a marketing authorization Firmagon ® throughout the European Union.

Pharmacokinetics

Degarelix is a depot preparation. Administered subcutaneously. After administration of testosterone was reduced within one week to castrate levels in 99% of patients.

Side effects

Disorders such as osteoporosis, fatigue and physical weakness, hot flashes, decreased libido and loss of erectile function and disturbance of memory function occur in all GnRH analogues. Specific for degarelix are allergic reactions that are supposed to be but significantly reduced compared to Abarelix.